• Home
  • Study Details
By physician referral or invitation only

A STUDY OF SELINEXOR AND VENETOCLAX WITH CHEMOTHERAPY IN PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA

The purpose of this study is to test the safety of the two study drugs, venetoclax and selinexor, and to find the highest dose of venetoclax and selinexor that can be given safely when it is combined with chemotherapy drugs (cytarabine or cytarabine and fludarabine). This study tests different doses of venetoclax and selinexor to see which dose is safer in children with leukemia.

Age & Gender

  • 1 months ~ 30 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

Thomas Alexander
Pediatrics - Hematology/Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Pediatric Cancers, Leukemia)
Child and Teen Health

IRB Number

22-0392

ClinicalTrials.gov

NCT04898894

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research